Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Role of intestinal microbiota, short-chain fatty acids, and endotoxemia in non-alcoholic fatty liver disease
FY 2012-13
Summary
About 20-30% of Canadians have non-alcoholic fatty liver disease, which is a fat buildup in the liver with or without inflammation. The disease can damage the liver and sometimes patients require a liver transplantation. It is not clear why some patients develop inflammation and therefore more severe disease. Scientists think that a number of factors can play a role, including diet and a person's genetic makeup. Very recently it has been discovered, that the kind of bacteria in the gut could also influence the course of fatty liver disease. Dr. Johane Allard, the candidate's supervisor, has recently received a grant from the Canadian Institutes of Health Research (CIHR) to examine this. The goal of the project is to describe the bacteria in the stool and to measure bacterial products in stool and blood of patients with fatty liver compared to healthy controls. The candidate will collect stool samples and blood from 60 patients with fatty liver disease (30 with fat only, 30 with fat plus inflammation in their liver) and 30 healthy living liver donors as healthy controls. In addition, patients will write down their food intake and their physical activity for one week, and they will fill out a questionnaire to assess other factors that can influence the gut microflora, including country of origin and use of antibiotics.
This study is new and important, as it could lead to new treatments for patients with fatty liver disease. If the gut bacteria are different in patients with fatty liver, we might in the future try to treat fatty liver with beneficial bacteria (probiotics) or carbohydrates that promote the growth of these "good" bacteria (prebiotics).
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
282073
Name
Da Silva Hannah E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Role of intestinal microbiota, short-chain fatty acids, and endotoxemia in non-alcoholic fatty liver disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
16s Rna Sequencing; Bifidobacteria; Endotoxin; Gas-Chromatography; Intestinal Microbiota; Limulus Amebocyte Lysate Assay; Non-Alcoholic Fatty Liver Disease; Real-Time Pcr; Short-Chain Fatty Acids; Steatohepatitis
Abstract
About 20-30% of Canadians have non-alcoholic fatty liver disease, which is a fat buildup in the liver with or without inflammation. The disease can damage the liver and sometimes patients require a liver transplantation. It is not clear why some patients develop inflammation and therefore more severe disease. Scientists think that a number of factors can play a role, including diet and a person's genetic makeup. Very recently it has been discovered, that the kind of bacteria in the gut could also influence the course of fatty liver disease. Dr. Johane Allard, the candidate's supervisor, has recently received a grant from the Canadian Institutes of Health Research (CIHR) to examine this. The goal of the project is to describe the bacteria in the stool and to measure bacterial products in stool and blood of patients with fatty liver compared to healthy controls. The candidate will collect stool samples and blood from 60 patients with fatty liver disease (30 with fat only, 30 with fat plus inflammation in their liver) and 30 healthy living liver donors as healthy controls. In addition, patients will write down their food intake and their physical activity for one week, and they will fill out a questionnaire to assess other factors that can influence the gut microflora, including country of origin and use of antibiotics.
This study is new and important, as it could lead to new treatments for patients with fatty liver disease. If the gut bacteria are different in patients with fatty liver, we might in the future try to treat fatty liver with beneficial bacteria (probiotics) or carbohydrates that promote the growth of these "good" bacteria (prebiotics).
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Da Silva, Hannah E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~